Ingredion heads into its third-quarter report with a problem plant fixed but the stock still behaving as if it is broken. Management spent its last call arguing that the worst of the Argo disruption was over and that its specialty business was gaining speed. The market has not bought it yet. Shares have fallen 8.3% since that report while the S&P 500 edged higher, leaving the stock near $94.71, just above its post-earnings low of $93.72 and well beneath its 200-day moving average of about $106. This quarter is the first clean look at whether the recovery story shows up in the numbers.

The Street is not asking for much. Consensus calls for earnings of $2.55 per share on revenue of $1.77 billion, a 7.3% decline in profit and a 2.5% slip in sales from a year ago, and a step down from the $2.82 earned last quarter. Some of that contraction is mechanical. The sale of the majority stake in the Pakistan business removes a profit contributor from the second half and pushes the All Other segment toward a roughly $15 million operating loss for the year. The full-year outlook tells a more demanding story, however. Management narrowed its 2026 range to $10.30 to $10.90 per share, yet consensus sits at $10.81, close to the top. Analysts are effectively betting that the back half runs smoothly, which leaves little room for fresh setbacks.

Argo is the first test. The Illinois facility absorbed a $40 million hit in the first quarter alone, then suffered an April thermal event that knocked germ processing offline. Management said the plant exited June at normal rates with margins up about 400 basis points sequentially. A full quarter of steady output should help the Food and Industrial Ingredients US-Canada segment, even though its full-year profit guide has been cut twice, now to a 20% to 25% decline. Results that track that lowered bar would validate the turnaround; any hint of renewed downtime or extra reliability spending would undercut management's central claim. Softer US food and beverage demand is the secondary risk here.

Texture and Healthful Solutions carries the growth narrative. Volume rose 7% last quarter, its ninth straight gain, and management lifted segment profit guidance to mid-to-high single digit growth with protein fortification sales climbing more than 40%. The complication is tapioca. Root prices are up more than 40% this year on Thai weather, and management warned of a lag of one to one and a half quarters before pricing catches up. That puts the third quarter squarely in the squeeze window. Continued volume momentum with only a temporary margin dip would confirm the thesis; slowing volume alongside compressed margins would suggest the raised guidance was premature.

Latin America adds currency noise. Mexico remains weak with a persistent peso headwind, and management flagged that the sharp July drop in the Argentine peso would land in this quarter. Beyond the quarter, updates on closing the Tate & Lyle acquisition, which won shareholder approval and promises more than 15% EPS accretion, and on how a competitor's planned closure of about 5% of US capacity could shape 2027 contracting may matter as much as the headline figures.

Sentiment has softened from outright gloom, with bearish readings easing from 55.6% to 44.0%, but the share price shows skepticism remains entrenched. The decisive question is whether a fully functioning Argo and a still-growing specialty franchise can absorb tapioca inflation and currency drag well enough to keep the full-year range, and the Street's high-end expectation, intact.